MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 124 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.16 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $6,947,968 | +11.2% | 24,800 | +6.0% | 0.01% | +25.0% |
| Q1 2024 | $6,248,736 | +26.2% | 23,400 | +9.3% | 0.00% | 0.0% |
| Q4 2023 | $4,951,532 | +53.4% | 21,400 | -3.2% | 0.00% | +33.3% |
| Q3 2023 | $3,227,484 | -49.6% | 22,100 | -20.2% | 0.00% | -25.0% |
| Q2 2023 | $6,398,700 | +2.0% | 27,700 | +6.9% | 0.00% | 0.0% |
| Q1 2023 | $6,274,534 | -25.2% | 25,900 | -10.4% | 0.00% | -33.3% |
| Q4 2022 | $8,388,225 | +357.6% | 28,900 | +2.5% | 0.01% | +500.0% |
| Q3 2022 | $1,833,000 | -9.2% | 28,200 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,019,000 | -15.3% | 28,200 | +16.0% | 0.00% | 0.0% |
| Q1 2022 | $2,384,000 | +27.9% | 24,300 | +10.5% | 0.00% | 0.0% |
| Q4 2021 | $1,864,000 | +6.2% | 22,000 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,755,000 | -15.0% | 22,000 | +3.8% | 0.00% | 0.0% |
| Q2 2021 | $2,065,000 | -23.2% | 21,200 | -7.8% | 0.00% | -50.0% |
| Q1 2021 | $2,690,000 | +6.6% | 23,000 | +1.3% | 0.00% | 0.0% |
| Q4 2020 | $2,524,000 | -6.3% | 22,700 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $2,695,000 | +6.2% | 22,700 | +1.3% | 0.00% | 0.0% |
| Q2 2020 | $2,537,000 | +130.2% | 22,400 | +35.8% | 0.00% | +100.0% |
| Q1 2020 | $1,102,000 | -25.3% | 16,500 | +1.9% | 0.00% | -50.0% |
| Q4 2019 | $1,476,000 | +7.7% | 16,200 | +1.9% | 0.00% | +100.0% |
| Q3 2019 | $1,371,000 | -16.7% | 15,900 | +1.3% | 0.00% | -50.0% |
| Q2 2019 | $1,646,000 | -6.2% | 15,700 | +12.1% | 0.00% | 0.0% |
| Q1 2019 | $1,754,000 | +14.4% | 14,000 | +2.9% | 0.00% | 0.0% |
| Q4 2018 | $1,533,000 | -42.7% | 13,600 | +8.8% | 0.00% | -33.3% |
| Q3 2018 | $2,677,000 | -23.4% | 12,500 | 0.0% | 0.00% | -25.0% |
| Q2 2018 | $3,496,000 | +147.4% | 12,500 | +3.3% | 0.00% | +100.0% |
| Q1 2018 | $1,413,000 | +29.4% | 12,100 | +1.7% | 0.00% | +100.0% |
| Q4 2017 | $1,092,000 | – | 11,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |